# A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

> **NCT00913835** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 125 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **BIOLOGICAL:** Olaratumab
- **DRUG:** liposomal doxorubicin

## Key facts

- **NCT ID:** NCT00913835
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-10
- **Final completion:** 2014-02
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913835, "A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00913835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*